Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

This study is testing whether, for people with liver cancer (hepatocellular carcinoma, or HCC) whose disease is growing in only a few spots (called oligoprogression) while on first-line treatment, it's better to add targeted radiation to those spots versus switching to a new drug regimen entirely. **You may be eligible if...** - You have been diagnosed with primary liver cancer (HCC) at an advanced stage (BCLC stage C) - You are on a first-line systemic treatment and only 1–5 specific spots are growing while others remain stable - The growing spots can safely be treated with radiation **You may NOT be eligible if...** - Your cancer is spreading widely (more than 5 sites or more than 3 organs) - You cannot safely receive radiation to the progressing spots - You have serious liver dysfunction or organ failure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.